Efficacy and safety of PCSK9 inhibitors combined with statins in acute ischemic stroke: a systematic review and meta-analysis.

In 30 seconds

This systematic review and meta-analysis of randomized controlled trials compared PCSK9 inhibitors plus statins with statins alone in patients with acute ischemic stroke. Combination therapy was associated with greater functional independence (modified Rankin Scale 0–2: OR = 2.17, 95% CI 1.29-3.64) and lower recurrent ischemic stroke risk (OR = 0.33, 95% CI 0.16-0.69). LDL-C was also reduced, while NIHSS scores and reported safety outcomes did not differ significantly. The authors judged evidence certainty moderate for functional independence, but low or very low for most other outcomes, and called for larger trials.

Key findings

• Functional independence (mRS 0–2) was more likely with combination therapy: OR = 2.17, 95% CI 1.29-3.64, P = 0.003.
• Recurrent ischemic stroke risk was lower with PCSK9 inhibitor plus statin therapy: OR = 0.33, 95% CI 0.16-0.69, P = 0.003.
• LDL-C was reduced with combination therapy (MD = 0.66 mmol/L, 95% CI 0.45-0.87), with high heterogeneity (I 2 = 86%).
• NIHSS scores and reported safety outcomes, including abnormal liver function, MACE, and total adverse events, showed no significant between-group differences.

Why it matters

The findings suggest that adding PCSK9 inhibition to statin therapy after acute ischemic stroke may be associated with better functional outcomes and fewer recurrent ischemic strokes. However, certainty varies by outcome, and the absence of significant differences in NIHSS and safety measures limits conclusions about broader benefit and harms. These results help frame the evidence while larger trials are awaited.

What to keep in mind

The authors describe the evidence as preliminary and call for larger, adequately powered randomized trials. Certainty was low for recurrent stroke, LDL-C, and safety outcomes, and very low for NIHSS; LDL-C and NIHSS analyses also showed substantial heterogeneity.